Investigational drug · Phase 3
Radiprodil
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for GRIN-related Neurodevelopmental Disorder, Tuberous Sclerosis Complex, Focal Cortical Dysplasia.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
10
Any phase or sponsor naming "Radiprodil"
First trial start
2024
Jul 10, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Radiprodil", any sponsor or status.
Conditions studied
As listed on its trial records.
- GRIN-related Neurodevelopmental Disorder
- Tuberous Sclerosis Complex
- Focal Cortical Dysplasia
Largest trials
Live from ClinicalTrials.gov: studies naming "Radiprodil" as an intervention, largest first.
- Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental DisorderPivotal-lookingRecruiting
GRIN Therapeutics, Inc.Industry
NCT07224581 · 100 participants (planned) · Start Jan 5, 2026 · Primary completion May 2027
Drug: Radiprodil; Placebo · For: GRIN-related Neurodevelopmental Disorder
Sites: Los Angeles, California; Palo Alto, California; Aurora, Colorado · 61 sites in all
GRIN Therapeutics, Inc.Industry
NCT07457229 · 40 participants (planned) · Start Mar 3, 2026 · Primary completion May 2027
Drug: Radiprodil · For: Hepatic Impairment
Sites: DeSoto, Texas; San Antonio, Texas
- A Study to Evaluate the Effect of Carbamazepine or Itraconazole on Radiprodil in Healthy Adult ParticipantsActive, not recruiting
GRIN Therapeutics, Inc.Industry
NCT07884734 · 36 participants (planned) · Start Jun 8, 2026 · Primary completion Oct 31, 2026
Drug: Radiprodil; Carbamazepine and 1 more · For: Healthy Adult Participants
Sites: Glendale, California
- Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type IIActive, not recruiting
GRIN Therapeutics, Inc.Industry
NCT06392009 · 30 participants (planned) · Start Jul 10, 2024 · Primary completion Jun 2026
Drug: Radiprodil · For: Tuberous Sclerosis Complex; Focal Cortical Dysplasia
Sites: South Brisbane, Australia; Leuven, Belgium; Calgary, Canada · 18 sites in all
GRIN Therapeutics, Inc.Industry
NCT06965881 · 30 participants · Start May 8, 2025 · Primary completion Jul 8, 2025
Drug: Radiprodil with Carbamazepine; Radiprodil with Itraconazole · For: Tuberous Sclerosis Complex (TSC); Focal Cortical Dysplasia; Other Neurological Disorders
Sites: Brisbane, Australia; Melbourne, Australia
- A Phase 1b Study of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder Caused by Non-Gain-of-Function VariantsNot yet recruiting
GRIN Therapeutics, Inc.Industry
NCT07941206 · 27 participants (planned) · Start Dec 2026 · Primary completion Oct 2027
Drug: Radiprodil; Placebo · For: GRIN-related Neurodevelopmental Disorder Caused by Variants Characterized as Non-Gain-of-Function
- Honeycomb: Evaluation of Radiprodil in Children with GRIN-related DisorderActive, not recruiting
GRIN Therapeutics, Inc.Industry
NCT05818943 · 24 participants (planned) · Start Mar 7, 2023 · Primary completion Nov 2026
Drug: Radiprodil · For: GRIN-related Disorders
Sites: Bethesda, Maryland; New York, New York; South Brisbane, Australia · 15 sites in all
GRIN Therapeutics, Inc.Industry
NCT06975605 · 18 participants · Start May 20, 2025 · Primary completion Jul 10, 2025
Drug: Radiprodil + co-administered drugs · For: Tuberous Sclerosis Complex (TSC); Focal Cortical Dysplasia; Other Neurological Disorders
Sites: Melbourne, Australia
NCT02647697 · 10 participants · Start Jan 2016 · Primary completion Feb 2016
Drug: Radiprodil oral · For: Healthy Volunteers
Sites: Groningen, Netherlands
NCT02829827 · 3 participants · Start Dec 4, 2017 · Primary completion Oct 2, 2018
Drug: Radiprodil · For: Infantile Spasms (IS)
Sites: Paris, France
Newest research
PubMed records naming it or its code names, newest first.
- NMDA receptor subunit-dependent analysis of radiprodil inhibition in neonatal male rat substantia nigra dopaminergic neurons.
Liu B, Gibb AJ · Br J Pharmacol 2026
- Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development.
Bialer M, Johannessen Landmark C, Koepp MJ, et al. · Epilepsia 2026
- Antiseizure Medications in Development: Novel Mechanisms, Precision Therapy, and the Move Towards Disease Modification.
Martins WA · Curr Issues Mol Biol 2026
- Inhibition of GluN2B-containing N-methyl-D-aspartate receptors by radiprodil.
Banke TG, Regan MC, Perszyk RE, et al. · Brain 2026
- New advances in small molecule drugs targeting NMDA receptors.
Zeng Y, Qu ZY, Zhu QW, et al. · Acta Pharmacol Sin 2026
- Current and Emerging Precision Therapies for Developmental and Epileptic Encephalopathies.
Samanta D, Bhatia S, Hunter SE, et al. · Pediatr Neurol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.